Session Information
-
WCLC 2017
18th World Conference on Lung Cancer
Conference Program for the 18th World Conference on Lung Cancer in Yokohama, Japan
Download PDF of the Conference Program: Click Here.
Onsite Conference Program Addendum (17/10/2017): Click Here.
Download PDF of the Abstract Book: Click Here.
Financial Disclosure Summary (PDF): Click Here.Presentation Date(s):- Oct 15 - 18, 2017
- Total Presentations: 2295
October 14 Sat
Oct 14 Sunday
October 15 Sun
Oct 15 Monday
October 16 Mon
Oct 16 Tuesday
October 17 Tue
Oct 17 Wednesday
October 18 Wed
Oct 18
-
+
JCSE 01 - Joint IASLC/CSCO/CAALC Session: Immunotherapy for Management of Lung Cancer: Ongoing Research from East and West
- 07:30 - 11:30
- 10/15/2017
- Location: F203 (Annex Hall)
- Type: Joint Session IASLC/CSCO/CAALC
- Track: Immunology and Immunotherapy
- Moderators:C. Bai, Fred R. Hirsch, Tony SK Mok, Yi-Long Wu
-
+
- Abstract
Loading... -
+
JCSE 01.24 - Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART)
11:30 - 11:30 | Presenter: Tony SK Mok | Author(s): Shun Lu, Ying Cheng, Jie Wang, Y. Wang, T. Wang, T. Yung, X. Su, F. Sun, F. Sun, L.T. Wang, Yi-Long Wu
- Abstract
Loading...
-
+
P1.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P1.01-032 - Detection of EGFR, ALK and Other Driver Oncogenes from Plasma cfDNA by Single Molecule Amplification and Re-sequencing Technology (cSMART)
09:30 - 09:30 | Presenter: Tony SK Mok | Author(s): Shun Lu, Ying Cheng, Jie Wang, Y. Wang, T. Wang, T. Yung, X. Su, F. Sun, L.T. Wang, Yi-Long Wu
- Abstract
Loading... -
+
P1.01-037 - Circulating Tumor DNA Clearance During Treatment Associates with Improved Progression-Free Survival
09:30 - 09:30 | Presenter: Shun Lu | Author(s): Yong Song, Z. Xie, Z. Zhu, Li Liu, Min Li, X. Dong, M. Jin, Jie Hu, C. Rao, G. Tong, D. Zheng, W. Zhao, Y. Chen, H. Han-Zhang, H. Xu, X. Mao, L. Zhang, H. Liu, J. Ye
- Abstract
Loading...
-
+
P1.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/16/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P1.04-010 - CheckMate 870: An Open-label Safety Study of Nivolumab in Previously Treated Patients With Non-Small Cell Lung Cancer in Asia
09:30 - 09:30 | Presenter: Shun Lu | Author(s): Li Zhang, Ying Cheng, Jie Wang, C. Wang, M. Wang, X. Li, Q. Wu, Yi-Long Wu
- Abstract
Loading...
-
+
MA 02 - Emerging Targets
- 11:00 - 12:30
- 10/16/2017
- Location: Room 511 + 512
- Type: Mini Oral
- Track: Clinical Design, Statistics and Clinical Trials
- Moderators:Ravi Salgia, Shun Lu
-
+
MA 02.01 - Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitors
11:00 - 11:05 | Presenter: Ticiana A. Leal | Author(s): T. Campbell, A. Mapes, K. Schneider, M.J. Staab, K. Velastegui, J.G. Christensen, I. Chen, A. Traynor
- Abstract
Loading... -
+
MA 02.02 - Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
11:05 - 11:10 | Presenter: Luis Paz-Ares | Author(s): B.P. Levy, Giuseppe Giaccone, Benjamin Besse, Enriqueta Felip, Marina Chiara Garassino, M. Domine, Pilar Garrido, B. Piperdi, S. Ponce Aix, R. Slepetis, X. Wu, A. Fandi
- Abstract
Loading... -
+
MA 02.03 - Selective Histone Deacetylase Inhibitor ACY-241 Plus Nivolumab for Refractory Advanced NSCLC: Results From a Phase 1b Study
11:10 - 11:15 | Presenter: Mark Awad | Author(s): Y. Le Bruchec, R. Markelewicz, P. Chen, A. Fandi, A. Spira
- Abstract
Loading... -
+
MA 02.04 - Discussant - MA 02.01, MA 02.02, MA 02.03
11:15 - 11:30 | Presenter: Grace K Dy
- Abstract
No abstract available for this presentation
-
+
MA 02.05 - Nivolumab in Advanced Non-Squamous NSCLC Patients with KRAS Mutations: Results from the Italian Expanded Access Program (EAP)
11:30 - 11:35 | Presenter: Domenico Galetta | Author(s): A. Ardizzoni, P. Bidoli, R. Chiari, L. Bonomi, D. Turci, L. Landi, L. Toschi, M. De Tursi, G. Francini, M. Giordano, O. Alabiso, A. De Censi, L. Livi, A. Berruti, M. Minelli, E. Ricevuto, A. Illiano, G. Puppo, A. Delmonte
- Abstract
Loading... -
+
MA 02.06 - BRAF Mutant NSCLC: Correlation with PD-L1 Expression,TMB, MSI and Response to ICPi and Anti-BRAF Therapy
11:35 - 11:40 | Presenter: Elizabeth Dudnik | Author(s): Nir Peled, M. Wollner, Amir Onn, A. Agbareya, H. Nechushtan, T. Kuznetsov, L.C. Roisman, A. Belilovski Rozenblum, Smadar Geva, A. Zer, Jair Bar
- Abstract
Loading... -
+
MA 02.07 - A Phase II Study of Pembrolizumab in EGFR Mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC
11:40 - 11:45 | Presenter: Aaron Lisberg | Author(s): J. Hunt, N. Reese, T. Wang, P. Coluzzi, M. Spiegel, K. Bornazyan, J. Carroll, J. Madrigal, B. Ledezma, M. Mendenhall, J.L. Bui, H. Lu, A. Cummings, Z. Noor, Jonathan W. Goldman, Edward Brian Garon
- Abstract
Loading... -
+
MA 02.08 - Discussant - MA 02.05, MA 02.06, MA 02.07
11:45 - 12:00 | Presenter: Barbara Melosky
- Abstract
No abstract available for this presentation
-
+
MA 02.09 - A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC
12:00 - 12:05 | Presenter: Don Lynn Gibbons | Author(s): L. Byers, David E Gerber, J. Peguero, D. Micklem, M. Yule, J. Lorens
- Abstract
Loading... -
+
MA 02.10 - Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC
12:05 - 12:10 | Presenter: Jonathan Wade Goldman | Author(s): E. Angevin, J. Strickler, D. Ross Camidge, R. Heist, D. Morgensztern, M. Barve, H. Yue, J. Beaulieu, M. Motwani, D. Afar, L. Naumovski, Karen Kelly
- Abstract
Loading... -
+
MA 02.11 - A Phase I Trial of Erlotinib and Onalespib in EGFR-mutant NSCLC: Focus on EGFR Exon 20 Insertions
12:10 - 12:15 | Presenter: Jonathan W Riess | Author(s): Karen L Reckamp, J. Longmate, Karen Kelly, David R. Gandara, Philip Christopher Mack, E. Newman, Primo Lara
- Abstract
Loading... -
+
MA 02.12 - Discussant - MA 02.09, MA 02.10, MA 02.11
12:15 - 12:30 | Presenter: Dean A Fennell
- Abstract
No abstract available for this presentation
-
+
MA 03 - Chemotherapy
- 11:00 - 12:30
- 10/16/2017
- Location: Room 502
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:Jin-Hyoung Kang, W. Su
-
+
MA 03.03 - Nedaplatin plus Docetaxel versus Cisplatin plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung
11:10 - 11:15 | Presenter: Shun Lu | Author(s): Z. Chen, C.P. Hu, R. Xin-Ling, Y. Chen, Yong Song, Z. Qiong, Yun Fan, W. Gang, M. Zhi-Yong, Jian Fang, Y. Qi-Tao, Z. Liu
- Abstract
Loading...
-
+
MA 08 - Supportive Care and Communication
- 11:00 - 12:30
- 10/17/2017
- Location: Room 511 + 512
- Type: Mini Oral
- Track: Nursing/Palliative Care/Ethics
- Moderators:E. Esposito-Nguyen, John McPhelim
-
+
MA 08.02 - Efficacy of Single-Dose NEPA versus 3-Day Aprepitant Regimen for Prevention of CINV: A Phase 3 Lung Cancer Subset Analysis
11:05 - 11:10 | Presenter: Shun Lu | Author(s): Li Zhang, A. Dechaphunkul, C. Lanzarotti, K. Jordan, M. Aapro
- Abstract
Loading...
-
+
MA 07 - ALK, ROS and HER2
- 15:45 - 17:30
- 10/17/2017
- Location: Room 316
- Type: Mini Oral
- Track: Advanced NSCLC
- Moderators:Robert C. Doebele, J.C. Ho
-
+
P3.01 - Advanced NSCLC
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
-
+
P3.01-026 - Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC
09:30 - 09:30 | Presenter: Martin Schuler | Author(s): James Chih-Hsin Yang, Lecia V Sequist, Yi-Long Wu, Caicun Zhou, S.L. Geater, Tony SK Mok, E. Tan, C. Hu, Nobuyuki Yamamoto, J. Feng, Kenneth Obyrne, Shun Lu, Vera Hirsh, Y. Huang, S. Ellis, C. Samuelsen, A. Märten, J. Fan, Keunchil Park, Luis Paz-Ares
- Abstract
Loading... -
+
P3.01-043 - Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung
09:30 - 09:30 | Presenter: Shirish M Gadgeel | Author(s): Glenwood Goss, Enriqueta Felip, M. Cobo, Shun Lu, K. Syrigos, K.H. Lee, E. Göker, V. Georgoulias, W. Li, S. Guclu, D. Isla, Y. Joo Min, A. Morabito, A. Ardizzoni, N. Gibson, N. Krämer, F. Solca, A. Cseh, E. Ehrnrooth, J. Soria
- Abstract
Loading... -
+
- Abstract
Loading... -
+
- Abstract
Loading... -
+
P3.01-075 - Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC
09:30 - 09:30 | Presenter: Vera Hirsh | Author(s): E. Tan, Yi-Long Wu, Lecia V Sequist, Caicun Zhou, Martin Schuler, S.L. Geater, Tony SK Mok, C. Hu, Nobuyuki Yamamoto, J. Feng, Kenneth Obyrne, Shun Lu, Y. Huang, M. Sebastian, Isamu Okamoto, N. Dickgreber, R. Shah, M. Palmer, A. Märten, D. Massey, C. Samuelsen, James Chih-Hsin Yang
- Abstract
Loading...
-
+
P3.02 - Biology/Pathology
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
-
+
P3.04 - Clinical Design, Statistics and Clinical Trials
- 09:30 - 16:00
- 10/18/2017
- Location: Exhibit Hall (Hall B + C)
- Type: Poster Session with Presenters Present
- Track: Clinical Design, Statistics and Clinical Trials
-
+
P3.04-005 - PD-L1 and Other Immuno-Markers Influenced by Osimertinib Treatment in Advanced Non-Small Cell Lung Cancer Patients (ATHENE Study)
09:30 - 09:30 | Presenter: Shun Lu | Author(s): Yongfeng Yu, H. Jian
- Abstract
Loading...
